Judge Lets Most Of Xyrem Antitrust Suit Against Jazz Survive
A California federal judge has largely refused to dismiss antitrust multidistrict litigation accusing Jazz Pharmaceuticals of staving off generic competition to its blockbuster narcolepsy drug Xyrem through a web of anticompetitive...To view the full article, register now.
Already a subscriber? Click here to view full article